ADC Therapeutics Medical Information Hub

Effusion and edema management Flashcard

Cutaneous Reactions management Flashcard

LOTIS-7 Dosing Infographic

{Bispecifics, glofitamab, LOTIS-7 dosing, mosunetuzumab, }

Mistry et al Case Study on Photosensitivity rash associated with ZYNLONTA®

ZYNLONTA (loncastuximab tesirine-lpyl)-Skin Reactions Management

{Artificial light, Cutaneous, Dermatologic, Erythema, Hyperpigmentation, Maculopapular, nail, photosensitivity, Pruritis, Rash, Skin, Sunlight, telangiectasia, }

ZYNLONTA (loncastuximab tesirine-lpyl) – LOTIS-2 Study

{b cell, diffuse large B-cell, DLBCL, Lotis, Lotis 2, lymphoma, NHL, non-hodgkin, phase 2, }

ZYNLONTA (loncastuximab tesirine-lpyl) – Temperature Excursion Data

{Dilution, excursion, handling, integrity, reconstitution, refrigerate, refrigerated, ship, shipping, stability, storage, store, temperature, temperature cycling, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Prior & Post-Radiation Use

{radiation, radiation therapy, radiotherapy, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Incidence of Richter’s Transformation

{incidence of richters, richers, richters transformation, }

ZYNLONTA (Loncastuximab tesirine-lpyl) – Premedication

{adverse, AE, dexamethasone, pre-medication, premedication, reaction, reactions, steroid, TEAE, }

Investigational (Loncastuximab tesirine) in treatment of MZL

Investigational Loncastuximab Tesirine–LOTIS-5 Study

{diffuse large B-cell lymphoma, DLBCL, gemcitabine, LOTIS 5, oxaliplatin, R-GEMOX, rituximab, }

Investigational Loncastuximab Tesirine-Ipyl – LOTIS-7 Clinical Trial

{CD20, CD3, glofitamab, lotis-7, mosunetuzumab, polatuzumab, polatuzumab vedotin, polivy, T-cell, }

LOTIS 5 infographic

{Lonca + R, LOTIS 5, R + gemcitabine +oxaliplatin, R-GEMOX, }

ZYNLONTA (loncastuximab tesirine-lpyl) – Renal Safety and PTLD

{adverse, AE, anuria, bladder, creatinine, disorders, dysuria, hematuria, hydronephrosis, incontinence, nocturia, pollakiuria, proteinuria, reaction, renal, retention, spasm, TEAE, ureterolithiasis, urinary, }

ZYNLONTA (loncastuximab tesirine-lpyl) – Use in Overweight Obese Patients

{ABW, Adjusted body weight, BMI, body mass index, obese, obesity, weight-adjusted, weight-adjusted dose, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Use in Patients with Hepatic Impairment

{alanine aminotransferase, alkaline phosphatase, ALP, ALT, aspartate aminotransferase, AST, bilirubin, gamma-glutamyltransferase, GGT, hepatic, liver, pharmacokinetic, pharmacokinetics, ULN, }

ZYNLONTA (loncastuximab tesirine-lpyl) – Use in Elderly Patients

{age, elderly, older, }

ZYNLONTA (loncastuximab tesirine-lpyl)-CD19 Expression, Response and Treatment

{CAR-T,exploratory, CD19, CD19 expression, chimeric antigen receptor T-cell, immunophenotypic, }

ZYNLONTA (loncastuximab-tesirine-Ipyl) – Infection Prophylaxis

{infection, infection prophylaxis, prophylactic use, prophylaxis, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Use in Patients with p53 Mutation

{mutate, mutated, mutation, mutations, p53, p53 mutations, }

ZYNLONTA (loncastuximab) Use Before or After Stem Cell Transplant

{allogeneic, autologous, HCT, hematopoietic cell transplantation, SCT, stem cell, transplant, transplantation, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Subsequent CAR-T

{CAR-T, chimeric antigen therapy, sequencing, }

ZYNLONTA (Loncastuximab-tesirine-Ipyl) Rationale for Dose Selection

{AUC, DLT, dose, dose-escalation, dose-expansion, dose-limiting, dose-selection, maximum tolerated, MTD, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Incidence of Nausea and Vomiting

{antiemetic, chemotherapy induced nausea and vomiting, CINV, emesis, nausea, vomit, vomiting, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Specific Gravity

{density, specific gravity, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Calculating Dose Based on ABW

{ABW, Adjusted body weight, BMI, body mass index, conversion, convert, dosage, dose, dosing, obese, obesity, overweight, weight, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Infusion Line of Administration

{administration, catheter, central, central device, central line, device, peripheral, peripheral device, peripheral line, Peripherally inserted central catheter, PICC, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Reinitiating After Missed Cycle

{dosage, dose, dose delay, dose interruption, dosing, missed cycle, missed dose, }

ZYNLONTA (loncastuximab tesirine-Ipyl)-Rationale for ABW Calculation

{ABW, Adjusted body weight, Body surface area, BSA, Calculated, Calculation, Dose calculation, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Incidence of Tumor Lysis Syndrome

{Incidence of Tumor, Tumor lysis, tumor lysis syndrome, }

ZYNLONTA (loncastuximab tesirine-lpyl) – Maximum Dose and Final Concentration

{concentration, Dilution, dosage, dose, dosing, max, maximum, overfill, reconstitution, }

ZYNLONTA (loncastuximab tesirine-Ipyl)-Storage and Stability of Vials

{Dilution, excursion, handling, reconstitution, refrigerate, refrigerated, stability, storage, store, temperature, temperature cycling, }

ZYNLONTA (Loncastuximab-tesirine-Ipyl)-Mechanism of Action

{mechanism, mechanism of action, mechanisms, MOA, }

ZYNLONTA (loncastuximab tesirine-lpyl) -Hypersensitivity_Incidence & Management

{Anaphylaxis, dexamethasone, Diphenhydramine, Hypersensitivity, Infusion-related, Methylprednisolone, prophylaxis, Ranitidine, }

ZYNLONTA (loncastuximab-tesirine-Ipyl) – Incidence of Cough

{Cough, Pneumonitis, Pulmonary edema, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Use in Patients with Renal Impairment

{creatinine, excreted, excretion, haemodialysis, hemodialysis, kidney, pharmacokinetic, pharmacokinetics, renal, renally, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Concomitant Use with Vaccines

{Inactivated, Inactivated vaccine, Influenza, Live vaccine, Live vaccines, Pneumococcal, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – LOTIS-1 Study

{B-NHL, burkitt lymphoma, CLL, DLBCL, double hit, follicular lymphoma, LOTIS 1, MCL, Phase 1, refractory, relapsed, triple hit, Waldenström's macroglobulinemia, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Bulky Disease and Burkitt Lymphoma

{bulky, burkitt, burkitt lymphoma, }

ZYNLONTA (loncastuximab tesirine-lpyl) – Incidence of Thrombocytopenia

{hematologic abnormalities, hematologic abnormality, Platelet, Platelet count, Platelet decrease, Platelet transfusion, Thrombocytopenia, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Use in Patients with CNS

{brain, central nervous system, CNS, leptomeningeal, leptomeningeal disease, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Inclusion of Patients with HGBCL

{7%, HGBCL, Inclusion of Patients with High Grade B-Cell Lymphoma, subgroup, subgroup analysis, }

ZYNLONTA (loncastuximab tesirine-Ipyl)-Use in Patients with Prior CAR T

{CAR, CAR-T, CART, CD-19, CD19, CD19 sequencing, cell therapy, chimeric antigen receptor, immunotherapy, T-cell, }

ZYNLONTA (loncastuximab tesirine-lpyl)- Extravasation_ Incidence & Management

{Extravasation, Injection site, IV infiltration, Pain, Subcutaneous, Subcutaneous infiltration, swelling, Tissue, Tissue damage, Ulcer, Ulceration, }

ZYNLONTA (loncastuximab) – Edema & Effusion_ Incidence & Management

{abdomen, adverse, AE, ascites, bloat, bloating, dexamethasone, diuretic, edema, effusion, fluid overload, oedema, pericardial, pericardiocentesis, pericarditis, pleurocentesis, pleuropericardial, pre-medication, premedication, reaction, reactions, spironolactone, swelling, TEAE, toxicities, toxicity, }

Investigational Loncastuximab Tesirine in the treatment of Follicular Lymphoma

ZYNLONTA (loncastuximab tesirine-lpyl) – Stability with Alternative Dilution

{0.05, 50 mL,100 mL, D5W, Dextrose, Dextrose for injection, Dextrose in water, Dilution, Filter, In-line filter, IV bag, Lactated ringer, lactated ringers, Normal saline, NS, osmolality, PAB, Partial additive bag, pH, PO, Polyolefin, Polyvinylchloride, PVC, Ringer, }

Loncastuximab tesirine-lpyl (ZYNLONTA) – NCCN Recommendations

{categorization, classification, diffuse large B-cell lymphoma, DLBCL, follicular lymphoma, guidelines, marginal zone lymphoma, National Comprehensive Cancer Network, NCCN, }

ZYNLONTA (loncastuximab tesirine-lpyl)- Latex Content

{latex, latex-free, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Prophylactic Use of Growth Factors

{G-CSF, granulocyte colony stimulating factor, growth factor, prophylaxis, }

ZYNLONTA (loncastuximab tesirine-lpyl)-Drug Interactions

{BCRP, bile salt export pump, bilesalt export pump, breast cancer resistance protein, BSEP, CYP, CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A4/5, CYP3A5, cytochrome, cytochrome P450, drug-drug, drug-interactions, glycoprotein, interactions, MATE, MATE1, MATE2-K, multi-antimicrobial extrusion, multiantimicrobial extrusion, OAT, OAT1, OAT2, OAT3, OATP, OATP1B1, OATP1B3, organic anion transporter, organic anion-transporting polypeptide, p-glycoprotein, p-gp, P450, }

ZYNLONTA (loncastuximab tesirine-lpyl) – Use in Pregnancy and Lactation

{birth defect, birth defects, breast milk, breastfed, breastfeed, contraception, embryo, embryotoxic, embryotoxicity, fertility, fetal, fetus, genotoxic, genotoxicity, infertile, infertility, lactate, lactation, milk, miscarriage, pregnancy, pregnant, reproduction, reproductive, teratogenic, teratogenicity, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Pharmacokinetics

{conjugated antibody, distribution, excretion, free fraction, in vitro, metabolism, pharmacokinetic, pharmacokinetics, pharmacology,, PK, plasma protein, plasma protein bound. absorption, serum, serum levels, SG3199, total antibody, }

ZYNLONTA (loncastuximab tesirine-Ipyl) – Incidence of Neutropenia

{adverse, AE, febrile, hematologic abnormalities, hematologic abnormality, neutropenia, neutrophil, reaction, reactions, TEAE, toxicities, toxicity, }